Research & Reports

As the unrivaled leader in benchmarking on corporate social investments, in partnership with companies, Chief Executives for Corporate Purpose® (CECP) found in its annual Giving in NumbersTM: 2020 Edition report that leading corporations are intensifying efforts to meet growing societal needs around the world.

Lots of the best minds in energy are in hyperdrive these days thinking about what a low-carbon grid looks like and how to get there. In a timely contribution to the field, E3 is out today with a major study of that question, as seen through the lens of PJM, one of the largest electricity markets in North America.

A task force set up to improve the reporting of financial risks caused by climate change has seen support for its recommendations soar in the past year as demand grew from investors for more information on how a warming planet will affect business.

The Task Force on Climate-related Financial Disclosures (TCFD), established by the Financial Stability Board (FSB), published its 2020 Status Report today.

We have an opportunity to respond in a way that helps drive meaningful and sustainable change for those who need it the most.

Organizations in Brazil, Portugal and eight other countries have improved access to the world’s most widely used standards for sustainability reporting, following publication of the GRI Standards in Portuguese.

In addition to the COVID-19 pandemic, the quest for greater social justice in 2020 has fueled companies to reexamine their diversity, equity and inclusion strategies, and they might take a page from Aflac’s commitment to a diverse workforce.

Disclosure highlights Company’s commitment to sustainability; since 2013, S&P Global has decreased greenhouse gas emissions 31% and energy use by 37% across its facilities.

During the COVID-19 pandemic, consumers are more willing than business executives to impose short-term economic pain for long-term gain, as trust in the government’s ability to make the world a better place has taken a plunge, as has environmental concerns.

From operational uncertainty and age-old budget constraints to outdated manual processes, CRB’s new Horizons: Cell and Gene Therapy report finds the biopharma industry at an important intersection of obstacle and opportunity.